Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response

PLoS Pathogens

Volumn 5, Issue 4, 2009, Pages

  Troyer, Ryan M ^a   McNevin, John ^b   Liu, Yi ^c   Zhang, Shao Chong ^d   Krizan, Randall W ^a   Abraha, Awet ^a   Tebit, Denis M ^a   Zhao, Hong ^c   Avila, Santiago ^a,e   Lobritz, Michael A ^a   McElrath, M Juliana ^b   Gall, Sylvie Le ^d   Mullins, James I ^c   Arts, Eric J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; EPITOPE; GAG PROTEIN; GLYCOPROTEIN GP 120; GP120 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HIV GAG PROTEIN P25; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; PEPTIDE FRAGMENT;

ANTIGEN PRESENTATION; ARTICLE; CYTOTOXIC T LYMPHOCYTE; EMBRYO; ENVELOPE GENE; GENE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; VIRUS GENOME; VIRUS REPLICATION; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; GENETICS; IMMUNOLOGY; METABOLISM; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MUTATION; PHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; EPITOPES, T-LYMPHOCYTE; EVOLUTION, MOLECULAR; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; VIRUS REPLICATION;

EID: 84857959077     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1000365     Document Type: Article

References (54)

1. Goulder PJ, Watkins DI (2004) HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol 4: 630-640.
2. Letvin NL (2005) Progress toward an HIV vaccine. Annu Rev Med 56: 213-223.
3. Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothe BR, et al. (2000) Tatspecific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407: 386-390.
4. Jones NA, Wei X, Flower DR, Wong M, Michor F, et al. (2004) Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med 200: 1243-1256.
5. Borrow P, Lewicki H,Wei X, HorwitzMS, Peffer N, et al. (1997) Antiviral pressure exerted byHIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 3: 205-211.
6. Cao J, McNevin J, Malhotra U, McElrath MJ (2003) Evolution of CD8+ T cell immunity and viral escape following acute HIV-1 infection. J Immunol 171: 3837-3846.
7. O'Connor DH, Allen TM, Vogel TU, Jing P, DeSouza IP, et al. (2002) Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med 8: 493-499.
8. Price DA, Goulder PJ, Klenerman P, Sewell AK, Easterbrook PJ, et al. (1997) Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci U S A 94: 1890-1895.
9. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, et al. (1997) Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 3: 212-217.
10. Feeney ME, Tang Y, Roosevelt KA, Leslie AJ, McIntosh K, et al. (2004) Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLAB27- positive long-term-nonprogressing child. J Virol 78: 8927-8930.
11. Barouch DH, Kunstman J, Glowczwskie J, Kunstman KJ, Egan MA, et al. (2003) Viral escape from dominant simian immunodeficiency virus epitopespecific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 77: 7367-7375.
12. Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, et al. (2005) Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J Virol 79: 13239-13249.
13. Liu Y, McNevin J, Cao J, Zhao H, Genowati I, et al. (2006) Selection on the human immunodeficiency virus type 1 proteome following primary infection. J Virol 80: 9519-9529.
14. O'Connor DH, McDermott AB, Krebs KC, Dodds EJ, Miller JE, et al. (2004) A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation. J Virol 78: 14012-14022.
15. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, et al. (2004) Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432: 769-775.
16. Leslie A, Kavanagh D, Honeyborne I, Pfafferott K, Edwards C, et al. (2005) Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med 201: 891-902.
17. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA (2002) Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296: 1439-1443.
18. Bhattacharya T, Daniels M, Heckerman D, Foley B, Frahm N, et al. (2007) Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 315: 1583-1586.
19. Brander C, Hartman KE, Trocha AK, Jones NG, Johnson RP, et al. (1998) Lack of strong immune selection pressure by the immunodominant, HLA-A*0201- restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. J Clin Invest 101: 2559-2566.
20. Meyerhans A, Dadaglio G, Vartanian JP, Langlade-Demoyen P, Frank R, et al. (1991) In vivo persistence of a HIV-1-encoded HLA-B27-restricted cytotoxic T lymphocyte epitope despite specific in vitro reactivity. Eur J Immunol 21: 2637-2640.
21. Liu Y, Mullins JI, Mittler JE (2006) Waiting times for the appearance of cytotoxic T-lymphocyte escape mutants in chronic HIV-1 infection. Virology 347: 140-146.
22. Domingo E, Holland JJ (1997) RNA virus mutations and fitness for survival. Annu Rev Microbiol 51: 151-178.
23. Fernandez CS, Stratov I, De Rose R, Walsh K, Dale CJ, et al. (2005) Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol 79: 5721-5731.
24. Friedrich TC, Dodds EJ, Yant LJ, Vojnov L, Rudersdorf R, et al. (2004) Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med 10: 275-281.
25. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, et al. (2004) HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10: 282-289.
26. Friedrich TC, Frye CA, Yant LJ, O'Connor DH, Kriewaldt NA, et al. (2004) Extraepitopic compensatory substitutions partially restore fitness to simian immunodeficiency virus variants that escape from an immunodominant cytotoxic-T-lymphocyte response. J Virol 78: 2581-2585.
27. Yeh WW, Cale EM, Jaru-Ampornpan P, Lord CI, Peyerl FW, Letvin NL (2006) Compensatory substitutions restore normal core assembly in simian immunodeficiency virus isolates with Gag epitope cytotoxic T-lymphocyte escape mutations. J Virol 80: 8168-8177.
28. Kelleher AD, Long C, Holmes EC, Allen RL, Wilson J, et al. (2001) Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27- restricted cytotoxic T lymphocyte responses. J Exp Med 193: 375-386.
29. Rimmelzwaan GF, Berkhoff EG, Nieuwkoop NJ, Fouchier RA, Osterhaus AD (2004) Functional compensation of a detrimental amino acid substitution in a cytotoxic-T-lymphocyte epitope of influenza a viruses by comutations. J Virol 78: 8946-8949.
30. Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, et al. (2007) Escape and compensation from early HLA-B57-mediated CTL pressure on HIV-1 Gag alters capsid interactions with cyclophilin A. J Virol 81: 12608-12618.
31. Draenert R, Le Gall S, Pfafferott KJ, Leslie AJ, Chetty P, et al. (2004) Immune Selection for Altered Antigen Processing Leads to Cytotoxic T Lymphocyte Escape in Chronic HIV-1 Infection. J Exp Med 199: 905-915.
32. Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, et al. (2006) Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J Virol 80: 3617-3623.
33. Matano T, Kobayashi M, Igarashi H, Takeda A, Nakamura H, et al. (2004) Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 199: 1709-1718.
34. Peyerl FW, Bazick HS, Newberg MH, Barouch DH, Sodroski J, Letvin NL (2004) Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope. J Virol 78: 13901-13910.
35. Liu Y, McNevin J, Zhao H, Tebit DM, Troyer RM, et al. (2007) Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitnessbalanced escape. J Virol 81: 12179-12188.
36. Gitti RK, Lee BM, Walker J, Summers MF, Yoo S, Sundquist WI (1996) Structure of the amino-terminal core domain of the HIV-1 capsid protein. Science 273: 231-235.
37. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, et al. (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025-1028.
38. Marozsan AJ, Arts EJ (2003) Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates. J Virol Methods 111: 111-120.
39. Anastassopoulou CG, Marozsan AJ, Matet A, Snyder AD, Arts EJ, et al. (2007) Escape of HIV-1 from a Small Molecule CCR5 Inhibitor Is Not Associated with a Fitness Loss. PLoS Pathog 3: e79. doi:10.1371/journal.ppat.0030079.
40. Lobritz MA, Marozsan AJ, Troyer RM, Arts EJ (2007) Natural Variation in the V3 Crown of Human Immunodeficiency Virus Type 1 Affects Replicative Fitness and Entry Inhibitor Sensitivity. J Virol 81: 8258-8269.
41. von Schwedler UK, Stray KM, Garrus JE, Sundquist WI (2003) Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol 77: 5439-5450.
42. van Baalen CA, Klein MR, Huisman RC, Dings ME, Kerkhof G, et al. (1996) Fine-specificity of cytotoxic T lymphocytes which recognize conserved epitopes of the Gag protein of human immunodeficiency virus type 1. J Gen Virol 77 (Pt 8): 1659-1665.
43. Frahm N, Adams S, Kiepiela P, Linde CH, Hewitt HS, et al. (2005) HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J Virol 79: 10218-10225.
44. Navis M, Schellens I, van Barle D, Borghans J, van Swieten P, et al. (2007) Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol 179: 3133-3143.
45. Le Gall S, Stamegna P, Walker BD (2007) Portable flanking sequences modulate CTL epitope processing. J Clin Invest 117: 3563-3575. doi:10.1172/JCI32047.
46. Quinones-Mateu ME, Arts EJ (2006) Virus fitness: concept, quantification, and application to HIV population dynamics. Curr Top Microbiol Immunol 299: 83-140.
47. Guillon C, Stankovic K, Taman-Onal Y, Biron F, Verrier B (2006) Evidence for CTL-mediated selection of Tat and Rev mutants after the onset of the asymptomatic period during HIV type 1 infection. AIDS Res Hum Retroviruses 22: 1283-1292.
48. Peut V, Kent SJ (2007) Utility of human immunodeficiency virus type 1 envelope as a T-cell immunogen. J Virol 81: 13125-13134.
49. Zuniga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, et al. (2006) Relative dominance of Gag p24-specific cytotoxic T lymphocytes is associated with human immunodeficiency virus control. J Virol 80: 3122-3125.
50. Frahm N, Kiepiela P, Adams S, Linde CH, Hewitt HS, et al. (2006) Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol 7: 173-178.
51. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27: 493-497.
52. Quinones-Mateu ME, Ball SC, Marozsan AJ, Torre VS, Albright JL, et al. (2000) A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol 74: 9222-9233.
53. Troyer RM, Collins KR, Abraha A, Fraundorf E, Moore DM, et al. (2005) Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 79: 9006-9018.
54. Cao J, McNevin J, Holte S, Fink L, Corey L, McElrath MJ (2003) Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)- specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol 77: 6867-6878.